References
1. Bouda, G.C., et al., Advanced Burkitt Lymphoma in Sub-Saharan
Africa Pediatric Units: Results of the Third Prospective Multicenter
Study of the Groupe Franco-Africain d’Oncologie Pédiatrique. J Glob
Oncol, 2019. 5 : p. 1-9.
2. Smith, M.A., et al., Declining childhood and adolescent cancer
mortality. Cancer, 2014. 120 (16): p. 2497-506.
3. Ozuah, N.W., et al., Five decades of low intensity and low
survival: adapting intensified regimens to cure pediatric Burkitt
lymphoma in Africa. Blood Adv, 2020. 4 (16): p. 4007-4019.
4. Cairo, M.S., et al., Results of a randomized international
study of high-risk central nervous system B non-Hodgkin lymphoma and B
acute lymphoblastic leukemia in children and adolescents. Blood, 2007.109 (7): p. 2736-43.
5. Patte, C., et al., Results of the randomized international
FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in
children and adolescents: it is possible to reduce treatment for the
early responding patients. Blood, 2007. 109 (7): p. 2773-80.
6. Gerrard, M., et al., Excellent survival following two courses
of COPAD chemotherapy in children and adolescents with resected
localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96
international study. Br J Haematol, 2008. 141 (6): p. 840-7.
7. Cairo, M.S., et al., Advanced stage, increased lactate
dehydrogenase, and primary site, but not adolescent age (≥ 15 years),
are associated with an increased risk of treatment failure in children
and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of
the FAB LMB 96 study. J Clin Oncol, 2012. 30 (4): p. 387-93.
8. Goldman, S., et al., Rituximab and FAB/LMB 96 chemotherapy in
children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s
Oncology Group report. Leukemia, 2013. 27 (5): p. 1174-7.
9. Goldman, S., et al., Rituximab with chemotherapy in children
and adolescents with central nervous system and/or bone marrow-positive
Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J
Haematol, 2014. 167 (3): p. 394-401.
10. Minard-Colin, V., et al., Rituximab for High-Risk, Mature
B-Cell Non-Hodgkin’s Lymphoma in Children. N Engl J Med, 2020.382 (23): p. 2207-2219.
11. Reiter, A., et al., Improved treatment results in childhood
B-cell neoplasms with tailored intensification of therapy: A report of
the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood, 1999.94 (10): p. 3294-306.
12. Wrobel, G., et al., Safety assessment of intensive induction
therapy in childhood anaplastic large cell lymphoma: report of the
ALCL99 randomised trial. Pediatr Blood Cancer, 2011. 56 (7): p.
1071-7.
13. Lowe, E.J., et al., Brentuximab vedotin in combination with
chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial
ANHL12P1. Blood, 2021. 137 (26): p. 3595-3603.